Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group.

2.50
Hdl Handle:
http://hdl.handle.net/10541/95940
Title:
Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group.
Authors:
Estlin, E J; Ablett, S; Newell, D R; Lewis, I J; Lashford, Linda S; Pearson, A D
Abstract:
The current recommendations for Phase I trials should allow more confident interpretation of the toxicity and efficacy of new agents by providing a framework for multicentre and international co-operation. An overview of the aims and designs of Phase I trials is presented, along with a summary of current and recently published United Kingdom Childrens Cancer Study Group Phase I trials, and a discussion of some of the difficulties faced in the methodology and evaluation of Phase I studies in children.
Affiliation:
Dept. of Child Health, Sir James Spence Institute of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Citation:
Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group. 1996, 14 (1):23-32 Invest New Drugs
Journal:
Investigational New Drugs
Issue Date:
1996
URI:
http://hdl.handle.net/10541/95940
DOI:
10.1007/BF00173679
PubMed ID:
8880390
Type:
Article
Language:
en
ISSN:
0167-6997
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorEstlin, E Jen
dc.contributor.authorAblett, Sen
dc.contributor.authorNewell, D Ren
dc.contributor.authorLewis, I Jen
dc.contributor.authorLashford, Linda Sen
dc.contributor.authorPearson, A Den
dc.date.accessioned2010-04-07T16:11:41Z-
dc.date.available2010-04-07T16:11:41Z-
dc.date.issued1996-
dc.identifier.citationPhase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group. 1996, 14 (1):23-32 Invest New Drugsen
dc.identifier.issn0167-6997-
dc.identifier.pmid8880390-
dc.identifier.doi10.1007/BF00173679-
dc.identifier.urihttp://hdl.handle.net/10541/95940-
dc.description.abstractThe current recommendations for Phase I trials should allow more confident interpretation of the toxicity and efficacy of new agents by providing a framework for multicentre and international co-operation. An overview of the aims and designs of Phase I trials is presented, along with a summary of current and recently published United Kingdom Childrens Cancer Study Group Phase I trials, and a discussion of some of the difficulties faced in the methodology and evaluation of Phase I studies in children.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshChild-
dc.subject.meshClinical Trials, Phase I as Topic-
dc.subject.meshEurope-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.titlePhase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group.en
dc.typeArticleen
dc.contributor.departmentDept. of Child Health, Sir James Spence Institute of Child Health, Royal Victoria Infirmary, Newcastle upon Tyne, UK.en
dc.identifier.journalInvestigational New Drugsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.